Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05102370 · ClinicalTrials.gov registry record · Phase 1
A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT05102370: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05102370 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05102370, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.
Interventions
- DRUG Enasidenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2026-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05102370
The ClinicalTrials.gov registry entry for NCT05102370 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enasidenib is the first listed.
NCT05102370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05102370 about?
NCT05102370 is a clinical study titled "A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance". Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective t...
What is the current status of trial NCT05102370?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2021-10-06. Estimated completion is 2026-01-26.
What interventions are being tested in trial NCT05102370?
The interventions under investigation include: Enasidenib (DRUG).
Who is sponsoring clinical trial NCT05102370?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.